Quick answer: Hormone therapy replaces estrogen, and often progesterone, that the ovaries stop producing during and after menopause. In November 2025 the FDA announced it would remove the boxed warning that had appeared on estrogen products for more than twenty years, and the first revised labels were approved in February 2026. For most healthy women who begin treatment within ten years of menopause and before age 60, current evidence points to a favorable balance of benefit and risk. Whether it fits you specifically still depends on your history, your symptoms, and a real conversation with a clinician.
The warning label that shaped two decades of decisions
If you were told at some point that hormone therapy causes breast cancer, heart attacks, and dementia, you were not misinformed. You were reading the label.
In 2002, early results from the Women’s Health Initiative changed prescribing overnight. Use of hormone therapy dropped sharply, and a boxed warning went onto estrogen products describing risks of stroke, blood clots, cardiovascular events, and dementia. That warning stayed there for over twenty years, and generations of women, along with plenty of physicians, treated it as the end of the discussion.
The problem was the population studied. WHI participants were, on average, considerably older than women who typically start hormone therapy for symptom relief, and many carried cardiovascular risk factors that skewed the results. Applying findings from women in their late 60s to a 51-year-old with disruptive night sweats was never a clean comparison, and researchers spent the following two decades saying so.
On November 10, 2025, the FDA agreed. HHS and the FDA announced actions revising safety labeling for menopausal hormone therapy, informing application holders that updated labeling would more clearly describe benefit and risk considerations for both systemic and local vaginal hormone products. The agency stated it would remove boxed warnings from all hormone therapy products containing estrogen, and the change covered more than twenty pills, patches, and creams containing hormones such as estrogen and progestin.
That was the announcement. The follow-through took a few months. On February 12, 2026, the FDA approved the first batch of revised labels, covering six products spanning progestogen-only, systemic estrogen-only, topical vaginal estrogen, and combined systemic formulations, with 29 manufacturers having submitted proposed updates.
What the new guidance actually says about timing
The label revision is not a blanket declaration that hormone therapy is risk-free. It is a shift toward age-specific guidance, and the timing detail matters more than anything else in this article.
Labels are being rewritten with age-specific guidance indicating that women may see long-term health benefits if hormone therapy is initiated within ten years of the onset of menopause. Randomized studies cited in the relabeling support favorable outcomes when therapy is started within that ten-year window, generally before age 60, including reductions in all-cause mortality and fractures.
Clinicians sometimes call this the timing hypothesis. Starting closer to the menopause transition appears to carry a different risk profile than starting fifteen years out. The Menopause Society, which supported the vaginal estrogen change, put it plainly: systemic estrogen still carries potential risks in certain individuals that should be reviewed in detail before starting therapy, and risks are low for younger, healthy women initiating treatment closer to the transition.
So the honest version is this. If you are 52, healthy, and waking up drenched three times a night, the evidence has moved in your favor. If you are 68 with a history of stroke, the conversation is different and needs to stay individualized.
Symptoms women in Brandon actually come in describing
Very few patients walk into our office at 122 S Moon Ave and say “I would like to discuss hormone therapy.” What we hear instead:
- Waking at 3 a.m. every night, soaked, then unable to fall back asleep
- Hot flashes during meetings, in the car on Bloomingdale Ave, in line at the grocery store
- A short fuse that does not match who you know yourself to be
- Brain fog, misplaced words, forgetting why you walked into a room
- Weight settling around the midsection despite no change in diet or activity
- Joint aches that arrived without an injury
- Painful intercourse, vaginal dryness, recurrent urinary symptoms
- Loss of interest in sex, and distress about that loss
Perimenopause is the part that catches people off guard. It can start in the early 40s, cycles stay mostly regular, and symptoms come and go unpredictably. Plenty of women get told their labs are normal and they should manage stress better. Hormone levels fluctuate wildly during this phase, which means a single blood draw can genuinely look unremarkable while you feel terrible. Symptom history often tells us more than the lab does.
The Florida heat problem nobody warns you about
There is a local wrinkle worth naming. Vasomotor symptoms and a Tampa Bay August are a miserable combination.
Hot flashes are a thermoregulatory problem — your body’s internal thermostat has become oversensitive, and it triggers a heat-dumping response over a much narrower temperature range than it used to. Ambient heat and humidity narrow that margin further. Women who moved here from cooler states routinely tell us their symptoms got noticeably worse after relocating, and they assumed it was coincidence or stress from the move. It usually is not.
Practical implication: if you are managing symptoms without medication, the window from roughly May through October in Hillsborough County is when strategies that worked in spring stop working. That is not failure. It is climate.
Delivery methods and what tends to drive the choice
Hormone therapy is not one product. It involves either estrogen alone or estrogen combined with progesterone, available as pills, patches, topical gels or creams, and low-dose vaginal estrogen.
A few notes on how the choice usually gets made:
Transdermal patches and gels bypass first-pass liver metabolism. For patients with certain cardiovascular or clotting risk considerations, that route is often preferred over oral.
Oral formulations are simple, familiar, and inexpensive. Fine for many patients.
Low-dose vaginal estrogen deserves separate mention because it is frequently and unnecessarily avoided. Only minimal amounts of estrogen are absorbed from the vagina into the bloodstream, so vaginal estrogen does not carry the same risks of stroke, blood clots, or cancer — which is exactly why the FDA panel pushed hardest on that particular warning. An analysis of nearly 57,000 postmenopausal women published in Stroke in August 2025 found that among older women who had already had one stroke, those using vaginal estrogen tablets were not more likely to have a second one.
Progesterone is added for any woman who still has a uterus, to protect the uterine lining. This is not optional and not negotiable.
If you have a uterus and someone offers you estrogen alone, find a different provider.
A word about “bioidentical” and compounded pellets
You will see heavy marketing in the Tampa Bay area for compounded bioidentical hormone pellets. Some clarity is useful here.
“Bioidentical” describes molecular structure, not sourcing or quality. Several FDA-approved products are structurally identical to human estradiol and progesterone. Those approved products have been through manufacturing consistency testing and carry standardized dosing.
Custom-compounded pellets are a different category. They are not FDA-approved, dosing consistency between batches varies, and once a pellet is inserted the dose cannot be adjusted or removed for months if you react poorly. Saliva testing used to justify custom dosing has not held up well against blood-based measurement.
None of that makes compounded therapy automatically wrong. It does mean the “custom, natural, individualized” framing is a marketing claim rather than a clinical advantage, and you deserve to know that before paying out of pocket for it.
Who should not start hormone therapy
Reasonable contraindications and cautions include:
- Current or prior hormone-sensitive breast cancer
- History of blood clots in the legs or lungs
- Prior stroke or heart attack
- Active liver disease
- Unexplained vaginal bleeding that has not been evaluated
- Known or suspected pregnancy
Women considering hormone therapy should discuss individual risk factors with their clinician, including history of heart attack or stroke, clotting events, hormone-sensitive cancer, active liver disease, and overall breast and cardiovascular risk. Family history matters, but it is one input among several rather than an automatic disqualification.
What a first visit at Brandon Medical Center looks like
We start with history, not a prescription pad. That means symptom timeline, menstrual pattern, prior pregnancies, medications and supplements, cardiovascular and cancer history on both sides of your family, and what you have already tried.
Baseline labs typically include a metabolic panel, lipids, thyroid function, and hormone levels where they add information. We check blood pressure and confirm your mammogram and Pap screening are current — hormone therapy does not replace age-appropriate screening, it sits alongside it.
If you are a candidate and want to proceed, we start at the lowest dose likely to control symptoms and reassess in about six to eight weeks. Symptom control, not a target number on a lab report, is the goal. Follow-up is annual at minimum once you are stable, and any unexpected bleeding gets evaluated promptly rather than watched.
Brandon Medical Center has served Brandon, Valrico, Riverview, Bloomingdale, Seffner, Lithia, and FishHawk since 2016. We are a small practice, which means you see the same people each visit and they remember your history without reading it off a screen.
Ready to talk it through?
If menopause symptoms are affecting your sleep, your work, or your relationships, that is reason enough for an appointment. You do not need to have reached a breaking point first.
Call Brandon Medical Center at (813) 502-6430 to schedule a hormone therapy consultation, or request an appointment online. We are at 122 S Moon Ave, Brandon, FL 33511, open Monday through Friday 8:30 a.m. to 7:00 p.m. and Saturday 8:30 a.m. to 4:00 p.m.
Frequently asked questions
Does the removal of the boxed warning mean hormone therapy is safe for everyone?
No. It means the previous warning was applied too broadly and did not reflect current evidence, particularly for younger women starting near the menopause transition. Individual contraindications still apply.
How long can I stay on hormone therapy?
There is no longer a fixed stopping date in most guidance. Duration is a periodic risk-benefit conversation rather than a countdown clock. Some women taper after a few years; others continue longer with ongoing monitoring.
Will insurance cover hormone therapy in Florida?
Many FDA-approved formulations are covered under standard pharmacy benefits, often at generic tiers. Compounded pellets typically are not. Coverage for the office visit depends on your plan, and our staff can tell you what to expect before you book.
Can I start hormone therapy if I am still having periods?
Yes. Perimenopausal treatment is common and often includes contraceptive considerations, since pregnancy remains possible during this phase.
Is weight gain during menopause treatable?
Partly. Hormonal shifts change where fat is stored and reduce lean muscle mass, which lowers resting metabolic rate. Hormone therapy addresses some of it. Many patients see better results pairing it with a structured medical weight loss program, which we offer in the same office.
How soon will I feel different?
Vasomotor symptoms often improve within two to four weeks. Sleep tends to follow. Mood, energy, and cognitive complaints usually take longer and are less predictable.
This article is general health information, not medical advice, and does not establish a patient-provider relationship. Hormone therapy decisions require individual evaluation by a licensed clinician.
